Technology

NTS is a bioinformatics platform built on tens of thousands of bulk RNA-seq samples from over thirty tissues, alongside dozens of single-cell datasets.

It identifies the transmembrane proteins unique to ageing and damaged tissues, ranking each by its therapeutic window, the fold-change in expression between diseased and healthy tissue, so treatments can engage senescent cells while preserving healthy ones.

We validate our targets at the protein level in senescent cells and in primary samples from patients, confirming expression in target cells, recurrence in IPF patients, and a lack of expression in healthy tissues.

Our team uses laboratory facilities and immunotherapy expertise at Institut Curie, with direct access to patient samples and clinical input through pulmonology centres in France.

Our lead targets are upregulated in senescence models and are also present in clinical lung biopsies.

Using proven therapeutic modalities from immuno-oncology, Neotis redirects the body’s cytotoxic T-cells straight to pathogenic senescent cells, forming a physical bridge between the immune system and the cells driving disease.

T-cell engagers are de-risked by clinical validation, with efficacy proven in more than ten oncology programmes, including in dense tissue.